trending Market Intelligence /marketintelligence/en/news-insights/trending/9-ckgmgmuae0bu2cnqaxaa2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Loxo Oncology completes rolling submission of FDA application for cancer drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Loxo Oncology completes rolling submission of FDA application for cancer drug

Loxo Oncology Inc. completed the rolling submission of its new drug application to the U.S. Food and Drug Administration for its cancer medicine larotrectinib.

The company seeks approval for the drug to treat solid tumors with the neurotrophic tyrosine receptor kinase, or NTRK, gene fusion that locally progressed or already spread. NTRK gene fusions are genetic alterations that can cause tumor growth.

Loxo Oncology initiated the rolling submission in December 2017. A marketing authorization application is expected to be filed with the EU in 2018.

The Stamford, Conn.-based company is co-developing the drug with Bayer AG.